Journal for ImmunoTherapy of Cancer

CELEBRATING A DECADE OF PUBLISHING AND MEDICAL ADVANCEMENT

First issue published May 29, 2013, with five papers, including:
- Introducing the Society for Immunotherapy of Cancer’s new journal: Journal for ImmunoTherapy of Cancer [Editorial]
- Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation [Review]

2016
Guidelines and Consensus Statements section added, leading to the publication of 30+ papers, including:
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
  - Top-read SITC Clinical Practice Guideline

Paper with all-time greatest Altmetric score published:
- Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

JITC’s most-read and cited paper of all time published:
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

2018
- JITC moves to continuous publication model to support the timely release of research

Notable series published in 2018:
- Microbial-Based Cancer Immunotherapy
- Emerging Immunotherapeutic Agents

2020
- Two new sections launched on emerging areas of the field:
  - Immune Cell Therapies and Immune Cell Engineering
  - Oncolytic and Local Immunotherapy

Notable series published:
- Immune Checkpoints Beyond PD-1

2021
First video abstract published:
- Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

Notable series published:
- COVID-19 and Cancer Immunotherapy

2022
- Published 10th Anniversary Editorial
- JITC achieves more than 40,000 total citations

Visit the JITC Anniversary page to learn more about the 10-year journey and major milestones.